

**Supplementary Table 1.** Treatment Duration by Regimen

Duration, wk	All patients		Genotype 1, %				Genotype 2, %		Genotype 3, %			Genotype 4, %	
	n	%	LDV/SOF	LDV/SOF+RIBA	PrOD	PrOD+RIBA	SOF+RIBA	LDV/SOF+RIBA	SOF+PEG+RIBA	SOF+RIB	LDV/SOF±RIBA	PrOD±RIBA	
n	17,487		8140 <sup>a</sup>	2692 <sup>a</sup>	776 <sup>a</sup>	2366 <sup>a</sup>	2131 <sup>a</sup>	392 <sup>a</sup>	140 <sup>a</sup>	715 <sup>a</sup>	103 <sup>a</sup>	32 <sup>a</sup>	
0 to <2	15	0.09	0.1	0	0.1	0	0.05	0	1.4	0.4	0	0	
2	424	2.4	1.9	1.7	4.1	4.3	2.5	2.3	0.7	3.2	2.9	3.1	
>2 to <4	15	0.09	0.07	0	0.0	0.04	0.3	0	0	0.1	0	0	
4	540	3.0	2.9	1.6	4.1	4.0	3.6	5.1	2.9	4.0	1.9	0	
>4 to <8	104	0.6	0.7	0.3	0.5	0.5	0.4	1.5	0.7	0.7	0.9	0	
0 to <8	1098	6.3	5.7	3.6	8.9	8.8	7.0	8.9	5.7	8.5	5.8	3.1	
8	2449	14	27	2.4	2.2	3.1	2.2	3.3	0.7	1.2	4.8	0	
>8 to <12	412	2.4	2.2	2.2	2.2	2.8	3.4	1.8	3.6	0.8	3.9	0	
12	10,609	61	50	78	81	77	66	78	74	3.2	68	88	
>12 to 16	1175	6.7	4.3	7	5.0	5.5	18	6.1	9.3	3.9	7.8	6.3	
>16 to 20	165	1.0	0.7	1.1	0.1	0.6	1.7	0	0	4.2	1.0	3.1	
>20 to <24	112	0.6	0.5	0.4	0.1	0.2	0.1	0.5	0	7.3	0	0	
≥24	1467	8.4	9.0	5.5	0	1.8	0.6	1.8	7.1	71	8.7	0	

<sup>a</sup>n.

**Supplementary Table 2.** Sustained Virologic Response Rates in Genotype 1–Infected Patients by Subgenotype 1a/1b, Cirrhosis, Prior Treatment and Duration of Treatment

	LDV/SOF		LDV/SOF+ RIBA		PrOD		PrOD + RIBA	
	n	SVR, % (95 CI)	n	SVR, % (95 CI)	n	SVR, % (95 CI)	n	SVR, % (95 CI)
Genotype 1a all patients	4723	92.3 (91.5–93.0)	1736	91.6 (90.2–92.9)	23	78.3 (55.2–91.3)	1500	91.7 (90.2–93.0)
Treatment-naïve								
No cirrhosis								
All durations	2870	92.8 (91.8–93.7)	378	96.6 (94.2–98.0)		NA	879	90.8 (88.7–92.5)
12 wk	1413	95.7 (94.5–96.6)	291	98.6 (96.4–99.5)		NA	725	95.0 (93.2–96.4)
24 wk						NA		
Cirrhosis								
All durations	745	89.8 (87.4–91.8)	428	89.0 (85.7–91.7)		NA	249	93.6 (89.7–96.0)
12 wk	527	91.7 (89.0–93.7)	341	91.2 (87.7–93.8)		NA	199	95.5 (91.5–97.6)
24 wk	95	93.7 (86.5–97.2)	19	94.7 (66.2–99.4)		NA		NA
Treatment-experienced								
No cirrhosis								
All durations	761	93.4 (91.4–95.0)	374	94.7 (91.8–96.5)		NA	285	93.0 (89.3–95.4)
12 wk	488	96.7 (94.7–98.0)	293	94.9 (91.7–96.9)		NA	224	94.6 (90.8–96.9)
24 wk	95	94.7 (87.8–97.8)				NA		
Cirrhosis								
All durations	347	90.8 (87.2–93.4)	556	88.3 (85.4–90.7)		NA	87	92.0 (83.9–96.2)
12 wk	75	90.7 (81.4–95.6)	421	88.8 (85.4–91.5)		NA	58	96.6 (86.7–99.2)
24 wk	205	94.1 (89.9–96.7)	60	91.7 (81.1–96.6)		NA		NA
Genotype 1b all patients	1768	93.3 (92.1–94.4)	566	93.6 (91.3–95.4)	627	95.2 (93.2–96.6)	480	94.2 (91.7–95.9)
Treatment-naïve								
No cirrhosis								
All durations	1095	94.1 (92.5–95.3)	115	96.5 (91.0–98.7)	462	96.1 (93.9–97.5)	179	93.9 (89.2–96.6)
12 wk	436	95.2 (92.7–96.8)	90	97.8 (91.3–99.5)	400	97.8 (95.7–98.8)	142	98.6 (94.5–99.7)
24 wk								
Cirrhosis								
All durations	252	90.9 (86.6–93.9)	108	92.6 (85.7–96.3)	30	96.7 (77.8–99.6)	173	93.1 (88.1–96.0)
12 wk	173	93.6 (88.8–96.5)	89	93.3 (85.6–97.0)	24	100	133	100
24 weeks	28	82.1 (62.1–92.8)		NA		NA		NA
Treatment-experienced								
No cirrhosis								
All durations	284	94.4 (91.0–96.5)	120	93.3 (87.1–96.7)	125	92.0 (85.7–95.7)	57	94.7 (84.4–98.4)
12 wk	183	95.6 (91.5–97.8)	93	94.6 (87.5–97.8)	104	99.0 (93.3–99.9)	48	97.9 (85.8–99.7)
24 wk	31	100						
Cirrhosis								
All durations	137	89.8 (83.4–93.9)	223	92.8 (88.6–95.6)		NA	71	97.2 (89.1–99.3)
12 wk	38	100	179	91.6 (86.5–94.9)		NA	60	100
24 wk	76	90.8 (81.6–95.6)		NA		NA		NA

NA, available; regimens with <20 patients. These are regimens not recommended for the specific subpopulation.

**Supplementary Table 3.** Sustained Virologic Response Rates by Genotype in Clinically Relevant Subpopulations

	Genotype 1	Genotype 2	Genotype 3	Genotype 4
All patients	92.8 (92.3–93.2)	86.2 (84.6–87.7)	74.8 (72.2–77.3)	89.6 (82.8–93.9)
No cirrhosis	93.6 (93.1–94.1)	89.1 (87.4–90.6)	81.6 (78.4–84.4)	91.5 (83.7–95.7)
Cirrhosis	90.6 (89.7–91.5)	77.3 (73.3–80.9)	65.7 (61.2–69.8)	83.9 (65.4–93.5)
FIB-4 score $\leq$ 3.25	93.5 (93.0–94.1)	89.2 (87.3–90.9)	83.8 (80.1–86.8)	91.3 (83.4–95.6)
FIB-4 score $>$ 3.25	91.2 (90.3–92.1)	80.8 (77.6–83.7)	66.5 (62.5–70.4)	84.4 (66.3–93.7)
HIV	92.1 (89.6–94.0)	91.1 (77.9–96.8)	95.5 (70.4–99.5)	90.0 (42.2–99.1)
Liver transplantation	95.7 (92.8–97.5)	91.7 (69.8–98.1)	88.2 (71.4–95.7)	50.0 (n = 2)
Treatment-naïve	92.8 (92.2–93.3)	88.0 (86.3–89.6)	77.5 (74.3–80.3)	88.3 (79.9–93.4)
Treatment-experienced	92.6 (91.7–93.3)	80.2 (76.2–83.6)	69.2 (64.2–73.9)	93.5 (76.1–98.5)

NOTE. Values are % (95% CI) unless otherwise indicated.

**Supplementary Table 4.** Sustained Virologic Response Rates in Treatment-Experienced Patients According to Prior Treatment Regimen

	Genotype 1		Genotype 2		Genotype 3	
	n	SVR, % (95% CI)	n	SVR, % (95% CI)	n	SVR, % (95% CI)
Prior Interferon	3574	92.8 (91.9–93.6)	413	80.1 (76.0–83.7)	329	68.1 (62.8–72.9)
Prior Boceprevir	865	94.7 (93.0–96.0)	—	—	—	—
Prior Telaprevir	212	90.1 (85.2–93.5)	—	—	—	—
Prior SOF	592	88.7 (85.9–91.0)	45	73.3 (58.0–84.5)	—	—
Prior Simeprevir+SOF	277	87.0 (82.5–90.5)	—	—	—	—
Prior PrOD	62	96.8 (87.6–99.2)	—	—	—	—
Prior LDV/SOF	122	87.7 (80.5–92.5)	—	—	—	—

**Supplementary Table 5.** Characteristics of Patients With or Without Available Hepatitis C Virus Viral Load Testing to Compute Sustained Virologic Response

Characteristic	SVR data	
	Absent (n = 1603)	Present (n = 15,884)
Race/ethnicity, %		
White, non-Hispanic	47	53
Black, non-Hispanic	30	29
Hispanic	9.1	4.8
Asian/Pacific Islander/American Indian/Alaska Native	1.3	1.6
Declined to answer, missing	11.7	12.1
Treatment duration, %		
0 to <8 wk	25	4.4
8 wk	15	14
>8 to <12 wk	2.7	2.3
12 wk	43	62
>12 to <24 wk	9.5	8.2
≥24 wk	5.2	8.7
Treatment duration, d, mean (SD)	71 (38)	87 (31)
HCV genotype, %		
1	77	80
2	14	12
3	8.9	7.0
4	0.62	0.80
Age, y, mean (SD)	59.4 (7.8)	61.0 (6.3)
Male, %	96.7	96.9
Treatment-experienced, %	24	30
HCV RNA viral load >6 million IU/mL, %	20	18
HIV co-infection, %	3.4	4.1
Cirrhosis, %	30	30
Decompensated cirrhosis, %	10.2	8.1
Hepatocellular carcinoma, %	3.5	2.7
Liver transplantation, %	1.7	2.3
Diabetes, %	26	30
Alcohol use or dependence, %	51	43
Substance use disorder, %	46	36
Depression, %	53	47
Post-traumatic stress disorder, %	29	27
Anxiety/panic, %	39	34
Schizophrenia, %	6.3	5.3
Laboratory results, %		
Anemia <sup>a</sup>	15.9	14.4
Platelet count <100 k/ $\mu$ L	14.4	13.5
Creatinine >1.1 mg/dL	18.7	19.9
Bilirubin >1.1 g/dL	16.0	13.8
Albumin <3.6 g/dL	21.3	20.3
INR >1.1	25.2	21.6
FIB-4 score >3.25, %	35.2	35.9

<sup>a</sup>Anemia is defined as a hemoglobin concentration <13 g/dL in men or <12 g/dL in women.